Galera claims pos­i­tive up­date in pan­cre­at­ic can­cer but does­n't re­port p-val­ues; Am­gen launch­es Cana­di­an fund in tan­dem with CCRM

Malvern, PA-based Galera Ther­a­peu­tics re­leased up­dat­ed fol­low-up da­ta Wednes­day af­ter­noon for a Phase I/II tri­al in pan­cre­at­ic can­cer, though it did not re­veal any p-val­ues as­so­ci­at­ed with the re­sults.

Ac­cord­ing to the com­pa­ny, af­ter six months of fol­low-up from 42 pa­tients with lo­cal­ly ad­vanced pan­cre­at­ic can­cer, the me­di­an over­all sur­vival was 20.1 months in the drug arm com­pared to 10.9 in the con­trol group for the GC4419 can­di­date. Ad­di­tion­al­ly, 29% of GC4419 pa­tients saw a par­tial re­sponse ver­sus just 11% on con­trol, Galera said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER